7.41

0.67% -0.05

After Hours: 7.41

Amneal Pharmaceuticals Inc (AMRX)

Overview News Price History Option Chain Discussions Forecast

Amneal Pharmaceuticals Inc stock is traded at $7.41, with a volume of 1.78M. It is down -0.67% in the last 24 hours and down -0.27% over the past month. Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Previous Close:

$7.46

Open:

$7.51

24h Volume:

1.78M

Relative Volume:

0.96

Market Cap:

$2.50B

Revenue:

$2.68B

Net Income/Loss:

$-184.45M

P/E Ratio:

-10.89

EPS:

-0.6805

Net Cash Flow:

$229.23M

1W Performance:

-7.03%

1M Performance:

-0.27%

6M Performance:

-15.12%

1Y Performance:

+14.53%

1-Day Range:

$7.41

$7.65

1-Week Range:

$7.145

$8.01

52-Week Range:

$6.29

$9.475

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name

Amneal Pharmaceuticals Inc

Sector

Healthcare (1153)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

908-947-3120

Address

400 Crossing Boulevard, 3rd Floor, Bridgewater

Employee

5,210

Twitter

@amnealpharma

Next Earnings Date

2025-05-02

Latest SEC Filings

AMRX's Discussions on Twitter

Compare AMRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AMRX Amneal Pharmaceuticals Inc	7.41	2.50B	2.68B	-184.45M	229.23M	-0.6805
ZTS Zoetis Inc	159.27	70.23B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.74	48.23B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	14.36	48.22B	30.25B	1.37B	5.08B	0.4257
TEVA Teva Pharmaceutical Industries Ltd Adr	16.93	18.57B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	301.42	13.29B	2.76B	1.11B	898.10M	22.77

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-25	Upgrade	JP Morgan	Neutral → Overweight
Sep-06-24	Upgrade	JP Morgan	Underweight → Neutral
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform
Mar-08-21	Upgrade	Goldman	Sell → Buy
Dec-14-20	Upgrade	Barclays	Equal Weight → Overweight
Dec-14-20	Upgrade	Guggenheim	Neutral → Buy
Jul-27-20	Initiated	Goldman	Sell
May-12-20	Upgrade	Guggenheim	Sell → Neutral
Dec-12-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-12-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jul-11-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-08-19	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight
May-21-19	Upgrade	Raymond James	Mkt Perform → Strong Buy
Mar-20-19	Initiated	SunTrust	Buy
Mar-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Dec-14-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-16-18	Downgrade	SunTrust	Buy → Hold
Aug-13-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jul-23-18	Initiated	Morgan Stanley	Overweight
Jun-22-18	Initiated	B. Riley FBR, Inc.	Buy

View All

Amneal Pharmaceuticals Inc Stock (AMRX) Latest News

May 09, 2025

Amneal Pharmaceuticals to add 200 jobs at its Brookhaven factory - Newsday

May 09, 2025

Does Amneal (AMRX) Have the Potential to Rally 54.16% as Wall Street Analysts Expect? - Nasdaq

May 09, 2025

Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals Stock? - Yahoo Finance

May 08, 2025

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal - GlobeNewswire

May 08, 2025

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced ... - Bluefield Daily Telegraph

May 08, 2025

Amneal Pharmaceuticals, Inc. and Apiject Systems, Corp. to Expand Sterile and Blow-Fill-Seal Capabilities for Advanced Pharmaceutical Manufacturing in the U.S - marketscreener.com

May 08, 2025

May 07, 2025

Amneal Pharmaceuticals, Inc. SEC 10-Q Report - TradingView

May 07, 2025

May 05, 2025

Amneal targets $3B-$3.1B in 2025 revenue with strong growth drivers - MSN

May 05, 2025

May 03, 2025

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 03, 2025